UK takes subscription approach for new antibiotics

Pills conceptual illustration

Source: © Jonathan McHugh/Ikon Images

Decoupling payment from prescriptions helps preserve last-line antibiotics and encourage R&D

The UK has adopted the world’s first subscription payment model for two new antibiotics. The National Health Service will pay Pfizer and Shionogi up to £10 million a year for ten years for them, regardless of how many doses are administered to patients.